Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 22350899)

1.

Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.

Gallastegui N, Groll M.

Methods Mol Biol. 2012;832:373-90. doi: 10.1007/978-1-61779-474-2_26.

PMID:
22350899
2.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

3.

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ.

Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Review.

PMID:
22726543
4.

[Development and clinical application of novel proteasome inhibitors].

Iida S.

Rinsho Ketsueki. 2012 Apr;53(4):417-25. Review. Japanese. No abstract available.

PMID:
22687975
5.

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.

Blackburn C, Gigstad KM, Hales P, Garcia K, Jones M, Bruzzese FJ, Barrett C, Liu JX, Soucy TA, Sappal DS, Bump N, Olhava EJ, Fleming P, Dick LR, Tsu C, Sintchak MD, Blank JL.

Biochem J. 2010 Sep 15;430(3):461-76. doi: 10.1042/BJ20100383. Erratum in: Biochem J. 2010 Oct 11;431(3):433.

6.

Proteasome inhibitors: an expanding army attacking a unique target.

Kisselev AF, van der Linden WA, Overkleeft HS.

Chem Biol. 2012 Jan 27;19(1):99-115. doi: 10.1016/j.chembiol.2012.01.003. Review.

7.

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.

8.

Clinical and marketed proteasome inhibitors for cancer treatment.

Zhang J, Wu P, Hu Y.

Curr Med Chem. 2013;20(20):2537-51. Review.

PMID:
23531219
9.

Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.

Kale AJ, McGlinchey RP, Lechner A, Moore BS.

ACS Chem Biol. 2011 Nov 18;6(11):1257-64. doi: 10.1021/cb2002544. Epub 2011 Sep 26.

10.

Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.

Groll M, Huber R.

Methods Enzymol. 2005;398:329-36.

PMID:
16275340
11.

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.

Cancer Cell. 2005 Nov;8(5):407-19.

12.

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG.

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. No abstract available.

PMID:
25005244
13.

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.

Gräwert MA, Groll M.

Chem Commun (Camb). 2012 Feb 1;48(10):1364-78. doi: 10.1039/c1cc15273d. Epub 2011 Oct 31. Review. Erratum in: Chem Commun (Camb). 2012 Dec 28;48(100):12255.

PMID:
22039589
14.

Targeting the proteasome pathway.

Tsukamoto S, Yokosawa H.

Expert Opin Ther Targets. 2009 May;13(5):605-21. doi: 10.1517/14728220902866851 . Review.

PMID:
19397479
15.

Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.

Tan X, Osmulski PA, Gaczynska M.

Curr Med Chem. 2006;13(2):155-65. Review.

PMID:
16472211
16.

Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.

Huber EM, Groll M.

Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8708-20. doi: 10.1002/anie.201201616. Epub 2012 Jun 18. Review.

PMID:
22711561
17.

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.

Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, Labutti J, Mazzola AM, Patil AD, Reimer CL, Solomon MS, Stirling M, Tian Y, Tsu CA, Weatherhead GS, Zhang JX, Rolfe M.

Mol Cancer Ther. 2006 Dec;5(12):3052-61.

18.
19.

Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.

Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I.

Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):62-77. Review.

PMID:
19275578
20.

Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).

Niewerth D, Jansen G, Riethoff LF, van Meerloo J, Kale AJ, Moore BS, Assaraf YG, Anderl JL, Zweegman S, Kaspers GJ, Cloos J.

Mol Pharmacol. 2014 Jul;86(1):12-9. doi: 10.1124/mol.114.092114. Epub 2014 Apr 15.

PMID:
24737138
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk